PPPP
Welcome to the Website of
Patient and Physician Perspective Project
dedicated to understanding breast cancer and its impact on patients and oncologists across Europe.
Breast cancer is a complex disease, and every individual's journey with it is unique. The project aims to collect perspectives from patients and oncologists at the forefront of research and clinical practice through survey conducted in various sites in Europe. The survey represents a strategy towards improvement of outcomes and support for those affected by breast cancer. Thank you for visiting, and thank you in advance for your contribution to this important endeavour.

ABOUT

Overview of the project

The project consists of a European-based research structured in 2 different Surveys targeted to patients with metastatic breast cancer with estrogen receptor (ER+) positive disease and oncologists specialized in the care of this condition. Object of the Surveys is to investigate the «Patient and Physician reported preferences». Results of the Surveys will contribute to advancements in the treatment of breast cancer and preparation of scientific publications to improve knowledge in the field.

Breast Cancer

Breast cancer is not a single disease; it encompasses various subtypes, each with distinct characteristics that influence treatment decisions and patients’ journeys. Every year, in Europe, over 550,000 patients are diagnosed with breast cancer. More than 147,000 patients die of this type of cancer in Europe every year. 70% of cases present estrogen-receptor (ER+) positive disease. Beyond its physical toll, breast cancer can have significant socio-economic implications for patients, families, and healthcare systems across Europe. Treatment strategies for breast cancer have advanced significantly in recent years, offering patients a range of options tailored to their specific subtype and individual needs.

Information about centres involved in the project

The Surveys will be addressed to Oncologists and Patients from various centres located in 4 countries in Europe (Italy, Germany, Spain, France) highly specialized in the diagnosis and treatment of breast cancers, identified through the support of Key Opinion Leaders (KOL) from the selected countries. The international approach of the project represents an added value, in terms of sharing expertise from KOLs in different countries.

THE SURVEYS

The two Surveys will employ 1000 Patients and 100 Oncologists, chosen from the 4 selected countries, after given their approval to participation. Each survey consists of various questions, designed for the different target audiences. The topics covered in the Surveys are mainly focused on the approaches and expectations about breast cancer therapeutic pathways.

The Surveys will be delivered to the patients and their physicians through a web-app on their mobile phones.

Main characteristics of the application:

Direct access via a link/QR code
Multilingual contents and services
Project presentation page
No registration form (no data collection from participants)
Mobile-responsive graphics
System for collecting and conducting a statistical analysis of the answers given

STEERING COMMITTEE MEMBERS

francia
germania
italia
spagna

Gilles Freyer: Medical Oncology Department, Institut de Cancérologie des HCL, Université de Lyon

Wolfgang Janni – Spokesperson of the AGO: Department of Obstetrics and Gynecology at the University of Ulm – Ulm

Andrea Botticelli: Policlinico Umberto I and la Sapienza University of Rome

Jose Angel Garcia Saenz: Hospital Clínico Universitario San Carlos, Madrid

Julien Peron: Oncology Department, CITOHL, Lyon-Sud Hospital, Cancer Institute of Hospices Civils de Lyon

Michael Untch: Head of the Clinic for Gynecology and Obstetrics, The Dept of Gynecologic Oncology and The Multidisciplinary Breast Cancer Center, Berlin

Saverio Cinieri: Medical Oncology Unit and Breast Unit, Hospital Perrino ASL Brindisi

Angel Guerrero: IVO (Instituto Valenciano de Oncología), Valencia

Thibaut Reverdy: Medical Oncology Department, Institut de Cancérologie des HCL, Université de Lyon

Alessandra Fabi: Director of operational Unit in medical precision in Senology at the IRCCS Policlinico universitario A. Gemelli, Rome

Tatiana Massarrah (nurse): Medical Oncology Research Unit, Hospital Gregorio Marañón, Madrid

francia

Gilles Freyer: Medical Oncology Department, Institut de Cancérologie des HCL, Université de Lyon

Julien Peron: Oncology Department, CITOHL, Lyon-Sud Hospital, Cancer Institute of Hospices Civils de Lyon

Thibaut Reverdy: Medical Oncology Department, Institut de Cancérologie des HCL, Université de Lyon

germania

Wolfgang Janni – Spokesperson of the AGO: Department of Obstetrics and Gynecology at the University of Ulm – Ulm

Michael Untch: Head of the Clinic for Gynecology and Obstetrics, The Dept of Gynecologic Oncology and The Multidisciplinary Breast Cancer Center, Berlin

italia

Andrea Botticelli: Policlinico Umberto I and la Sapienza University of Rome

Saverio Cinieri: Medical Oncology Unit and Breast Unit, Hospital Perrino ASL Brindisi

Alessandra Fabi: Director of operational Unit in medical precision in Senology at the IRCCS Policlinico universitario A. Gemelli, Rome

spagna

Jose Angel Garcia Saenz: Hospital Clínico Universitario San Carlos, Madrid

Angel Guerrero: IVO (Instituto Valenciano de Oncología), Valencia

Tatiana Massarrah (nurse): Medical Oncology Research Unit, Hospital Gregorio Marañón, Madrid

RESOURCES

FAQ

The survey is conducted by CD Pharma, in association with relevant oncology centres in 4 European Countries (France, Germany, Italy and Spain) and the support and the patronage of Scientific societies in the various countries. CD Pharma is a consulting service company specialized in supporting and management of projects in the field of pharma.

The purpose of the survey is to understand patients’ and physicians’ preferences in therapeutic management of patients with metastatic breast cancer in follow-up phases.

The data from the surveys will contribute to advancements in the treatment of breast cancer and will be used for preparation of scientific publications to improve knowledge in the field.

Yes, the survey is completely anonymous, and no personal data will be collected.

Yes, the participation to the survey is totally volunteering and no economical compensation is foreseen for the completion of the survey.

Each survey can be completed in 10-15 minutes approximately.

CONTACT INFORMATION

CD Pharma
Via Marghera, 43 – Milano IT

Email: helpdesk@cdpharma.it